keyword
MENU ▼
Read by QxMD icon Read
search

Ebola drugs

keyword
https://www.readbyqxmd.com/read/29028879/review-of-computational-methods-for-virus-host-protein-interaction-prediction-a-case-study-on-novel-ebola-human-interactions
#1
Anup Kumar Halder, Pritha Dutta, Mahantapas Kundu, Subhadip Basu, Mita Nasipuri
Identification of potential virus-host interactions is useful and vital to control the highly infectious virus-caused diseases. This may contribute toward development of new drugs to treat the viral infections. Recently, database records of clinically and experimentally validated interactions between a small set of human proteins and Ebola virus (EBOV) have been published. Using the information of the known human interaction partners of EBOV, our main objective is to identify a set of proteins that may interact with EBOV proteins...
September 26, 2017: Briefings in Functional Genomics
https://www.readbyqxmd.com/read/28994386/-integrating-clinical-research-into-epidemic-response-the-field-perspective-in-the-ebola-experience
#2
Denis Malvy, Daouda Sissoko, Alseny-Modet Camara
During the 2013-2016 west African Ebola outbreak that affected West Africa, accelerated clinical trials, testing unproven but promising and potentially lifesaving experimental interventions emerged as a key component of the global outbreak. In 2017, no Ebola medical countermeasures had proven antiviral efficacy in patients. However, in September 2014, the World Health Organization inventoried a list of potential drug candidates developed or repurposed with demonstrated antiviral efficacy in vitro or in animal models...
October 2017: Médecine Sciences: M/S
https://www.readbyqxmd.com/read/28968729/a-survey-on-ebola-genome-and-current-trends-in-computational-research-on-the-ebola-virus
#3
Pritha Dutta, Anup Kumar Halder, Subhadip Basu, Mahantapas Kundu
A detailed understanding of the Ebola virus (EBOV) pathogenesis has not been possible because of safety concerns, which arise while handling the live EBOV. Understanding the mechanisms involved in EBOV entry, replication and inhibition of the antiviral response in the host cell are crucial for the development of effective therapeutic measures. In this article, we provide a description of the EBOV genome and the role of each EBOV protein in spreading infection in the host cell. We also discuss some of the major computational works done on EBOV for the purpose of developing effective vaccines and drugs...
August 29, 2017: Briefings in Functional Genomics
https://www.readbyqxmd.com/read/28945945/macromolecular-antiviral-agents-against-zika-ebola-sars-and-other-pathogenic-viruses
#4
Franziska Schandock, Camilla Frich Riber, Annika Röcker, Janis A Müller, Mirja Harms, Paulina Gajda, Kaja Zuwala, Anna H F Andersen, Kaja Borup Løvschall, Martin Tolstrup, Florian Kreppel, Jan Münch, Alexander N Zelikin
Viral pathogens continue to constitute a heavy burden on healthcare and socioeconomic systems. Efforts to create antiviral drugs repeatedly lag behind the advent of pathogens and growing understanding is that broad-spectrum antiviral agents will make strongest impact in future antiviral efforts. This work performs selection of synthetic polymers as novel broadly active agents and demonstrates activity of these polymers against Zika, Ebola, Lassa, Lyssa, Rabies, Marburg, Ebola, influenza, herpes simplex, and human immunodeficiency viruses...
September 25, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28930583/ibuprofen-as-a-template-molecule-for-drug-design-against-ebola-virus
#5
Slobodan Paessler, Cheng Huang, Milan Sencanski, Nevena Veljkovic, Vladimir Perovic, Sanja Glisic, Veljjko Veljkovic
The Ebola virus outbreak in West Africa 2015 and Congo 2017, point out an urgent need for development of drugs against this important pathogen. Previously, by repurposing virtual screening of 6438 drugs from DrugBank, ibuprofen was selected as a possible inhibitor of the Ebola virus infection. The results of an additional docking analysis as well as experimental results showing measurable anti-Ebola effect of ibuprofen in cell culture suggest ibuprofen as a promising molecular template for the development of drugs for treatment of the infection by Ebola virus...
January 1, 2018: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28917841/graphene-vp40-interactions-and-potential-disruption-of-the-ebola-virus-matrix-filaments
#6
Jeevan B Gc, Rudramani Pokhrel, Nisha Bhattarai, Kristen A Johnson, Bernard S Gerstman, Robert V Stahelin, Prem P Chapagain
Ebola virus infections cause hemorrhagic fever that often results in very high fatality rates. In addition to exploring vaccines, development of drugs is also essential for treating the disease and preventing the spread of the infection. The Ebola virus matrix protein VP40 exists in various conformational and oligomeric forms and is a potential pharmacological target for disrupting the virus life-cycle. Here we explored graphene-VP40 interactions using molecular dynamics simulations and graphene pelleting assays...
November 4, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28890666/discovering-drugs-for-the-treatment-of-ebola-virus
#7
REVIEW
Sandra L Bixler, Allen J Duplantier, Sina Bavari
PURPOSE OF REVIEW: Ebola virus, a member of the Filoviridae family, is a causative agent of severe viral hemorrhagic fever in humans. Over the past 40 years, the virus has been linked to several high mortality outbreaks in Africa with the recent West African outbreak resulting in over 11,000 deaths. This review provides a summary of the status of the drug discovery and development process for therapeutics for Ebola virus disease, with a focus on the strategies being used and the challenges facing each stage of the process...
2017: Current Treatment Options in Infectious Diseases
https://www.readbyqxmd.com/read/28878087/novel-stable-ebola-virus-minigenome-replicon-reveals-remarkable-stability-of-the-viral-genome
#8
Wanyin Tao, Tianyu Gan, Mingzhe Guo, Yongfen Xu, Jin Zhong
Ebola virus (EBOV) causes severe hemorrhagic fever in humans and other primates with a high case fatality rate. No approved drug or vaccine of EBOV is available, which necessitates better understanding of the virus life cycle. Studies on EBOV have been hampered because experimentations involving live virus are restricted to biosafety level 4 (BSL-4) laboratories. EBOV minigenome system has provided researchers with the opportunity to study EBOV under BSL-2 conditions. Here, we developed a novel EBOV minigenome replicon which, to our knowledge, is the first EBOV cell culture system that can stably replicate and transcribe EBOV minigenome...
September 6, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28852537/ebola-and-fda-reviewing-the-response-to-the-2014-outbreak-to-find-lessons-for-the-future
#9
Emily A Largent
In 2014, West Africa confronted the most severe outbreak of Ebola virus disease (EVD) in history. At the onset of the outbreak-as now-there were no therapies approved by the U.S. Food and Drug Administration (FDA) for prevention of, post-exposure prophylaxis against, or treatment of EVD. As a result, the outbreak spurred interest in developing novel treatments, sparked calls to use experimental interventions in the field, and highlighted challenges to the standard approach to FDA approval of new drugs. Although the outbreak was geographically centered in West Africa, it showcased FDA's global role in drug development, approval, and access...
December 2016: Journal of Law and the Biosciences
https://www.readbyqxmd.com/read/28827211/development-and-deployment-of-the-openmrs-ebola-electronic-health-record-system-for-an-ebola-treatment-center-in-sierra-leone
#10
Shefali Oza, Darius Jazayeri, Jonathan M Teich, Ellen Ball, Patricia Alexandra Nankubuge, Job Rwebembera, Kevin Wing, Alieu Amara Sesay, Andrew S Kanter, Glauber D Ramos, David Walton, Rachael Cummings, Francesco Checchi, Hamish S Fraser
BACKGROUND: Stringent infection control requirements at Ebola treatment centers (ETCs), which are specialized facilities for isolating and treating Ebola patients, create substantial challenges for recording and reviewing patient information. During the 2014-2016 West African Ebola epidemic, paper-based data collection systems at ETCs compromised the quality, quantity, and confidentiality of patient data. Electronic health record (EHR) systems have the potential to address such problems, with benefits for patient care, surveillance, and research...
August 21, 2017: Journal of Medical Internet Research
https://www.readbyqxmd.com/read/28822631/clinical-evaluation-of-ebola-virus-disease-therapeutics
#11
REVIEW
Guodong Liu, Gary Wong, Shuo Su, Yuhai Bi, Frank Plummer, George F Gao, Gary Kobinger, Xiangguo Qiu
Ebola virus disease (EVD) was first described over 40 years ago, but no treatment has been approved for humans. The 2013-2016 EVD outbreak in West Africa has expedited the clinical evaluation of several candidate therapeutics that act through different mechanisms, but with mixed results. Nevertheless, these studies are important because the accumulation of clinical data and valuable experience in conducting efficacy trials under emergency circumstances will lead to better implementation of similar studies in the future...
August 16, 2017: Trends in Molecular Medicine
https://www.readbyqxmd.com/read/28820067/a-comprehensive-review-on-ebola-ebov-virus-future-prospects
#12
Sajad Khan, Muhammad, Abdur Rauf, Ahsan Khan, Muhammad Rizwan, Seema Patel, Haroon Khan, Adel M Mahasneh, Mohammad S Mubarak
Ebola virus (EBOV) was discovered for the first time in 1976. It belongs to the family Filoviridae, which causes hemorrhagic fever that could lead to death in a few days. West Africa faced a major outbreak where symptoms appeared in the form of chills, myalgia, fever, diarrhea, and vomiting, and the disease finally reached a severe state as a result of hemorrhagic complications and failure of multiple organs. EBOV spreads by contact with body fluids of an infected person such as blood, saliva, urine, and seminal fluid, and also spreads by a contact with contaminated surfaces...
August 16, 2017: Infectious Disorders Drug Targets
https://www.readbyqxmd.com/read/28807685/an-rna-polymerase-ii-driven-ebola-virus-minigenome-system-as-an-advanced-tool-for-antiviral-drug-screening
#13
Emily V Nelson, Jennifer R Pacheco, Adam J Hume, Tessa N Cressey, Laure R Deflubé, John B Ruedas, John H Connor, Hideki Ebihara, Elke Mühlberger
Ebola virus (EBOV) causes a severe disease in humans with the potential for significant international public health consequences. Currently, treatments are limited to experimental vaccines and therapeutics. Therefore, research into prophylaxis and antiviral strategies to combat EBOV infections is of utmost importance. The requirement for high containment laboratories to study EBOV infection is a limiting factor for conducting EBOV research. To overcome this issue, minigenome systems have been used as valuable tools to study EBOV replication and transcription mechanisms and to screen for antiviral compounds at biosafety level 2...
August 12, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28794491/ebola-virus-vp24-interacts-with-np-to-facilitate-nucleocapsid-assembly-and-genome-packaging
#14
Logan Banadyga, Thomas Hoenen, Xavier Ambroggio, Eric Dunham, Allison Groseth, Hideki Ebihara
Ebola virus causes devastating hemorrhagic fever outbreaks for which no approved therapeutic exists. The viral nucleocapsid, which is minimally composed of the proteins NP, VP35, and VP24, represents an attractive target for drug development; however, the molecular determinants that govern the interactions and functions of these three proteins are still unknown. Through a series of mutational analyses, in combination with biochemical and bioinformatics approaches, we identified a region on VP24 that was critical for its interaction with NP...
August 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28761574/repurposed-therapeutic-agents-targeting-the-ebola-virus-a-systematic-review
#15
Hussein Sweiti, Obinna Ekwunife, Thomas Jaschinski, Stefan K Lhachimi
BACKGROUND: The Ebola virus has been responsible for numerous outbreaks since the 1970s, with the most recent outbreak taking place between 2014 and 2016 and causing an international public health emergency. Ebola virus disease (EVD) has a high mortality rate and no approved targeted treatment exists to date. A number of established drugs are being considered as potential therapeutic agents for the treatment of EVD. OBJECTIVE: We aimed to identify potential drug repositioning candidates and to assess the scientific evidence available on their efficacy...
2017: Current Therapeutic Research, Clinical and Experimental
https://www.readbyqxmd.com/read/28750617/health-system-preparedness-for-integration-of-mental-health-services-in-rural-liberia
#16
Wilfred S Gwaikolo, Brandon A Kohrt, Janice L Cooper
BACKGROUND: There are increasing efforts and attention focused on the delivery of mental health services in primary care in low resource settings (e.g., mental health Gap Action Programme, mhGAP). However, less attention is devoted to systematic approaches that identify and address barriers to the development and uptake of mental health services within primary care in low-resource settings. Our objective was to prepare for optimal uptake by identifying barriers in rural Liberia. The country's need for mental health services is compounded by a 14-year history of political violence and the largest Ebola virus disease outbreak in history...
July 27, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28725019/high-dose-sertraline-monotherapy-fails-to-protect-rhesus-macaques-from-lethal-challenge-with-ebola-virus-makona
#17
Anna N Honko, Joshua C Johnson, Jonathan S Marchand, Louis Huzella, Ricky D Adams, Nicholas Oberlander, Lisa M Torzewski, Richard S Bennett, Lisa E Hensley, Peter B Jahrling, Gene G Olinger
The recent epidemic of Ebola virus disease in West Africa resulted in an unprecedented number of cases and deaths. Due to the scope of the outbreak combined with the lack of available approved treatment options, there was strong motivation to investigate any potential drug which had existing data reporting anti-Ebola activity. Drugs with demonstrated antiviral activity in the nonhuman primate models already approved for another indication or for which there was existing safety data were considered to be priorities for evaluation by the World Health Organization...
July 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28721965/the-rise-of-global-health-diplomacy-an-interdisciplinary-concept-linking-health-and-international-relations
#18
Vijay Kumar Chattu
Global health diplomacy (GHD) is relatively a very new field that has yet to be clearly defined and developed though there are various definitions given by different experts from foreign policy, global health, diplomacy, international relations, governance, and law. With the intensification of globalization and increasing gaps between countries, new and reemerging health threats such as HIV/AIDS, tuberculosis, influenza, severe acute respiratory syndrome, Ebola, and Zika and a gradual rethinking on security concepts framed a new political context...
April 2017: Indian Journal of Public Health
https://www.readbyqxmd.com/read/28709400/broad-range-potential-of-asphodelus-microcarpus-leaves-extract-for-drug-development
#19
Amalia Di Petrillo, Antonella Fais, Francesca Pintus, Celestino Santos-Buelga, Ana M González-Paramás, Vincenzo Piras, Germano Orrù, Antonello Mameli, Enzo Tramontano, Aldo Frau
BACKGROUND: Many plants have been used in traditional medicine for their antibacterial, antifungal, antiprotozoal, antiviral, antidiarrhoeal, analgesic, antimalarial, antioxidant, anti-inflammatory and anticancer activities. In order to find novel antimicrobial and antiviral agents, the aim of the present study was the evaluation of the antibacterial and antibiofilm susceptibility of Asphodelus microcarpus leaves extract. Moreover, the antiviral activity and the phytochemical composition of the active extract were also determined...
July 14, 2017: BMC Microbiology
https://www.readbyqxmd.com/read/28709136/tetracyclines-as-a-potential-antiviral-therapy-against-crimean-congo-hemorrhagic-fever-virus-docking-and-molecular-dynamic-studies
#20
Amirhossein Sharifi, Arash Amanlou, Faezeh Moosavi-Movahedi, Sahand Golestanian, Massoud Amanlou
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is one of the deadliest human diseases with mortality rate near 50%. Special attention should be paid to this virus since there is no approved treatment for it. On the other hand, the recent outbreak of Ebola virus which is a member of hemorrhagic fever viruses shows this group of viruses can be extremely dangerous. Previous studies have indicated that nucleoprotein of CCHFV, a pivotal protein in virus replication, is an appropriate target for antiviral drug development...
July 1, 2017: Computational Biology and Chemistry
keyword
keyword
40086
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"